Jazz Symposium
Jazz supported Industry Lunch Symposium (Hall A)
Friday, September 20th
10:45-12:15
Driving a change in outcomes for high-risk AML* and hepatic veno-occlusive disease
Chair: Dr Rafael Duarte, Spain
10:45 | Welcome and introduction Dr Rafael Duarte, Spain |
||
10:50 | Driving change in outcomes for high-risk AML* *High-risk AML defined as therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC) Prof. Thomas Cluzeau, France |
||
11:10 | Q&A | ||
11:20 | Surviving severe hepatic VOD: real-world evidence and new data Dr Rafael Duarte, Spain |
||
11:40 | Best practice in action in severe hepatic VOD Prof. José Pérez-Simón, Spain |
||
12:00 | Q&A | ||
12:10 | Summary and close Dr Rafael Duarte, Spain |
This symposium is funded and organised by Jazz Pharmaceuticals.
This symposium will contain promotional content and prescribing information will be available upon request and at the Jazz Pharmaceuticals exhibition stand.
Adverse events should be reported. Healthcare professionals are asked to report any suspected adverse events via their national reporting system.
In the United Kingdom: Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/
Adverse events should also be reported to Jazz Pharmaceuticals at
AEreporting@jazzpharma.com or by fax to +44 (0) 1865 598765